Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Financial Results:
Glenmark Life Sciences Ltd reported Revenues for Q2FY24 of ₹595.00 Crores up from ₹509.00 Crore year on year, a rise of 16.9%.
Total Expenses for Q2FY24 of ₹441.00 Crores up from ₹376.00 Crores year on year, a rise of 17.29%.
Consolidated Net Profit of ₹119.00 Crores up 11.21% from ₹107.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹9.69, up 11.12% from ₹8.72 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.